Starch-Entrapped Microsphere Fibers Improve Bowel Habit but Do Not Exhibit Prebiotic Capacity in Those with Unsatisfactory Bowel Habits: A Phase I, Randomized, Double-Blind, Controlled Human Trial by Rasmussen, Heather E. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Nutrition and Health Sciences -- Faculty
Publications Nutrition and Health Sciences, Department of
8-2017
Starch-Entrapped Microsphere Fibers Improve
Bowel Habit but Do Not Exhibit Prebiotic
Capacity in Those with Unsatisfactory Bowel
Habits: A Phase I, Randomized, Double-Blind,
Controlled Human Trial
Heather E. Rasmussen
Rush University Medical Center, heather.rasmussen@unl.edu
Bruce Hamaker
Purdue University, hamakerb@purdue.edu
Kumar B. Rajan
Rush University Medical Center, kumar_rajan@rush.edu
Ece Mutlu
Rush University Medical Center, ece_mutlu@rush.edu
Stefan J. Green
University of Illinois, greenDNA@uic.edu
This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Nutrition and Health Sciences -- Faculty Publications by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.
Rasmussen, Heather E.; Hamaker, Bruce; Rajan, Kumar B.; Mutlu, Ece; Green, Stefan J.; Brown, Michael; Kaur, Amandeep; and
Keshavarzian, Ali, "Starch-Entrapped Microsphere Fibers Improve Bowel Habit but Do Not Exhibit Prebiotic Capacity in Those with
Unsatisfactory Bowel Habits: A Phase I, Randomized, Double-Blind, Controlled Human Trial" (2017). Nutrition and Health Sciences --
Faculty Publications. 155.
http://digitalcommons.unl.edu/nutritionfacpub/155
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/nutritionfacpub
Part of the Human and Clinical Nutrition Commons, Molecular, Genetic, and Biochemical
Nutrition Commons, and the Other Nutrition Commons
Authors
Heather E. Rasmussen, Bruce Hamaker, Kumar B. Rajan, Ece Mutlu, Stefan J. Green, Michael Brown,
Amandeep Kaur, and Ali Keshavarzian
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/nutritionfacpub/155
 
 
 
Published in Nutrition Research 44 (August 2017), pp. 27–37; doi: 10.1016/j.nutres.2017.05.015 
Copyright © 2017 Elsevier Inc. Used by permission. 
Submitted October 21, 2016; revised May 19, 2017; accepted May 23, 2017; published online June 2, 2017. 
 
 
Starch-Entrapped Microsphere Fibers Improve 
Bowel Habit but Do Not Exhibit Prebiotic 
Capacity in Those with Unsatisfactory Bowel 
Habits: A Phase I, Randomized, Double-Blind, 
Controlled Human Trial 
 
 
Heather E. Rasmussen,1 Bruce Hamaker,2 Kumar B. Rajan,3 Ece Mutlu,4 
Stefan J. Green,5 Michael Brown,4 Amandeep Kaur,2 and Ali Keshavarzian4 
 
1. Department of Clinical Nutrition, Rush University Medical Center, Chicago, Illinois, USA 
2. Department of Food Science, Purdue University, West Lafayette, Indiana, USA 
3. Rush Institute for Healthy Aging, Department of Internal Medicine, Rush University Medical 
Center, Chicago, Illinois, USA 
4. Division of Digestive Diseases and Nutrition, Department of Internal Medicine, Rush University 
Medical Center, Chicago, Illinois, USA 
5. DNA Services Facility, Research Resources Center, University of Illinois, Chicago, Illinois, USA 
 
Corresponding author – Heather E. Rasmussen, Rush University Medical Center, 1700 W. Van Buren St., Ste. 425, 
Chicago, IL, USA 60612, telephone 312-942-4401, fax 312-942-5203, email heather_rasmussen@rush.edu 
Additional email addresses – Bruce Hamaker, hamakerb@purdue.edu; Kumar B. Rajan, kumar_rajan@rush.edu; Ece 
Mutlu, ece_mutlu@rush.edu; Stefan J. Green, greendna@uic.edu; Michael Brown, michael_brown@rush.edu; 
Amandeep Kaur, kaur1@purdue.edu; Ali Keshavarzian, ali_keshavarzian@rush.edu 
 
Abstract 
Approximately one-third of individuals in the United States experience unsatisfactory bowel habits, 
and dietary intake, especially one low in fiber, could be partly responsible. We hypothesized that 
intake of a fermentable fiber (starch-entrapped microspheres, SM) that has a delayed, slow fermen-
tation profile in vitro would improve bowel habit while exhibiting prebiotic capacity in those with 
self-described unsatisfactory bowel habits, all with minimal adverse effects. A total of 43 healthy 
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volunteers completed a 3-month,double-blind, parallel-arm randomized clinical trial to assess the 
ability of a daily dose (9 or 12 g) of SM vs. psyllium (12 g) to improve bowel habit, including stool 
consistency and frequency, and modify gut milieu through changes in stool microbiota and short-
chain fatty acids while remaining tolerable through minimal gastrointestinal symptoms. All out-
comes were compared before and after fiber treatment. Stool frequency significantly improved 
(P = .0003) in all groups after 3 months, but stool consistency improved only in both SM groups 
compared with psyllium. In addition, all groups self-reported a similar improvement in overall 
bowel habit with fiber intake. Both SM and psyllium resulted in minimal changes in microbiota com-
position and short-chain fatty acid concentrations. The present study suggests that supplementation 
with a delayed and slow-fermenting fiber in vitro may improve bowel habit in those with constipa-
tion, but further investigation is warranted to determine capacity to alter microbiota and fermenta-
tion profiles in humans. This trial was registered at ClinicalTrials.gov as NCT01210625. 
 
Keywords: prebiotics, dietary fiber, microbiota, constipation, clinical trial 
 
Abbreviations: BCFA, branched-chain fatty acid; BMI, body mass index; FDR, false-discovery rate; 
GEE, generalized estimating equations; OTU, operational taxonomic units; SCFA, short-chain fatty 
acid; SM, starch-entrapped microspheres 
 
1. Introduction 
 
The number of individuals who experience unsatisfactory bowel habits are increasing, 
with up to one-third of the population experiencing constipation [1], a condition that 
is defined by any of the following: fewer than 3 bowel movements per week, straining, 
hard stool, and a sense of incomplete evacuation [2]. The reason for this increase is not 
completely clear but likely involves several environmental factors including dietary intake 
of foods that are high in fat and refined carbohydrates and low in fiber such as fruit, veg-
etables, and complex carbohydrates [3]. Lack of adequate fiber intake may contribute to 
constipation-predominant unsatisfactory bowel habit because of fiber’s fecal bulking ca-
pacity or lack of substrate for fermentation, the byproducts of which (e.g., short-chain fatty 
acids [SCFAs]) support healthy colonic epithelial cells [4]; these attributes are dependent 
on the specific attributes of the fiber. 
Fiber supplements (primarily fiber capsules or fiber powders) commonly used for those 
with unsatisfactory bowel habit, including constipation, primarily consists of one of sev-
eral specific dietary fibers, with psyllium being one of the commonly recommended fiber 
supplements [5]. Psyllium has been reported in a number of studies to be a nonfermentable 
bulking fiber that functions in the colon by binding water and increasing viscosity [6,7]. 
Some evidence exists to support the supplementation of fibers such as psyllium to improve 
constipation, but data are limited [8]. In addition, several challenges and obstacles have 
been encountered for widespread use of fibers in general, as their intake often can result 
insignificant adverse effects such as gas, bloating, and gastrointestinal pain, especially in 
those that have unsatisfactory bowel habit [9]. These adverse effects could be due, in part, 
to the fermentation capacity of the fiber. While fermentable fibers may beneficially alter 
the intestinal milieu, fermentation is often rapid, causing gas production and bloating 
[10,11]. These adverse effects could lead to poor compliance and intake of less than an 
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optimal dose. Therefore, investigation into an alternative fermentable, nonbloating fiber 
supplement for constipation relief is warranted. 
To this end, we used our expertise in carbohydrate science to develop a novel, ferment-
able, starch-based, fiber-entrapped microsphere. Both in vitro and in vivo experiments re-
veal that these starch-entrapped microspheres (SM) are slowly fermented, allowing for 
delayed gas production and thus potentially increased tolerability as compared with con-
ventional fibers and current prebiotics [12–15]. Thus, we hypothesized that intake of SM 
would promote gut health by improving bowel habit and exhibiting prebiotic capacity, 
both with minimal adverse effects. Therefore, the primary objective of the study was to 
determine the ability of 2 daily doses of SM to improve bowel habit, including stool con-
sistency and frequency, and modify gut milieu (microbiota and SCFA) while remaining 
tolerable through minimal gastrointestinal symptoms (e.g., gas, bloating, abdominal pain) 
in those with self-described unsatisfactory bowel habit (constipation predominant). We 
used a randomized, double-blind, controlled trial with those with self-described unsatis-
factory bowel habits using psyllium as a comparator to meet our objective. 
 
2. Methods and materials 
 
2.1. Participants and study design 
This was a randomized, double-blind, controlled, 3-arm, parallel-group, phase I clinical 
trial conducted at Rush University Medical Center from January 2011 to July 2012. Indi-
viduals were included if they were 18- to 65-year-old men and women with self-described 
unsatisfactory bowel habits. Unsatisfactory bowel habit was defined by any of the following 
conditions: < 3 bowel movements per week, hard stool requiring straining, or sense of in-
complete defecation. Potential participants also had to report dissatisfaction with their 
bowel movements. Exclusion criteria included the following: (1) abnormal complete blood 
count values; (2) abnormal liver function test results; (3) low serum albumin (< 3 g/dL); 
(4) abnormal thyroid-stimulating hormone level; (5) elevated C-reactive protein (>5); 
(6) gastrointestinal symptoms except for occasional heartburn (< 3 times a week, not med-
ication dependent) or occasional fresh blood in stool from hemorrhoids; (7) prior intestinal 
resection; (8) history of gastrointestinal diseases (except for hemorrhoids or hiatal hernia); 
(9) antibiotic use within the last 12 weeks prior to enrollment; (10) underweight (body mass 
index [BMI] < 18.5 kg/m2); (11) significant cardiac or respiratory diseases, severe hyperten-
sion, insulin-requiring and/or poorly controlled diabetes (hemoglobin A1c > 6); (12) signif-
icant psychological disorders, drug and/or alcohol abuse; (13) unwillingness to consent to 
the study; (14) plan to have a major change in dietary habits during the following 5 months 
from time of enrollment; and (15) pregnant and lactating women because of lack of infor-
mation about safety of the product in this population. 
The study was 14 weeks in duration, with a 2-week initial run-in phase to ensure stabil-
ity of reported bowel habit and a 12-week treatment phase. Study participants participated 
in 3 face-to-face visits (visits 1–3) throughout the study. At visit 1, participants returned a 
completed 7-day food and bowel habit diary and provided fecal samples. During this visit, 
the health status of each study participant was assessed through a comprehensive ques-
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tionnaire, physical examination, and blood draw for complete blood count, Comprehen-
sive metabolic panel, and thyroid-stimulating hormone to determine eligibility to partici-
pate. If eligible, participants returned for visit 2 at the end of the 2-week run-in period and 
provided a second completed 7-day food and bowel habit diary; the bowel habit diary was 
used to determine if the subject had unsatisfactory bowel habits as previously described. 
Eligible participants were randomly assigned to 1 of 3 groups: 12 g psyllium, 9 g SM, or 12 
g SM. Randomization was concealed, and assigned numbers were computer generated by 
the statistician who was not involved in participant recruitment or outcome assessment 
and data analysis. Participants were then provided with the fiber supplements and con-
sumption instructions. After the completion of the 3-month treatment period, participants 
returned for visit 3 and provided food, gastrointestinal symptom, and bowel habit diaries 
completed daily during the last 7 days of each of the 3 months of the study. During the 
visit, health status was again assessed, and the number of capsules not consumed was rec-
orded and reconciled with a medication log to determine compliance. Participants were 
also encouraged to maintain their usual diets throughout the study period. During the 
3-month treatment phase, phone calls were made weekly to remind all participants to take 
their supplements and to inquire about their health and any new symptoms. 
The present study was conducted according to the guidelines laid down in the Declara-
tion of Helsinki, and all procedures were approved by the Institutional Review Board of 
Rush University Medical Center (approved April 2010). Written informed consent was ob-
tained from each participant before beginning the study. This trial was listed at Clinical-
Trials.gov as NCT01210625. 
 
2.2. Fiber treatments 
Starch-entrapped microspheres were prepared as previously described [15]. In brief, a sus-
pension of sodium alginate (2% w/v) and normal corn starch (9% w/v) was made in water 
and dropped through a 22-gauge hypodermic needle using a peristaltic pump (Tris; Tele-
dyne Isco, Lincoln, NE, USA) into a calcium chloride bath (4% w/v). The microspheres 
were kept in the bath for 1 to 4 hours, collected by filtration, thoroughly washed with wa-
ter, and then dried in a warm air oven at 45°C for 24 hours. All materials that constitute 
the SM supplement are currently marketed in the United States for food use (GRAS classi-
fied: cornstarch, 21CFR§182.70; sodium alginate, 21CFR§184.1724), and the microspheres 
were manufactured and packaged under proper standard operating procedures to ensure 
product safety. Psyllium was obtained from Natural Foods Inc (Toledo, OH, USA) and was 
selected as the comparator because of its common use as a fiber supplement with gentle 
bulk-forming laxative capabilities. Both the SM and psyllium were encapsulated in 1-g 
quantities; depending on randomization, participants consumed either 9 or 12 g each day. 
Participants were instructed to consume these 9 or 12 pills daily in 3 equal doses. A dose 
of 9 g and 12 g of SM was selected based on our pilot study in 10 participants with consti-
pation indicating that, after 1month of supplementation, a 9-g dose improved bowel habit 
(improvement in stool consistency from 2 to 4 on the Bristol Stool Scale [16]; range of +6 to 
+10 on a visual analog scale ranging from −10 [worsening of bowel movements] to 10 [im-
provement of bowel movements] with 0 indicating no change) and increased stool butyrate 
concentration (P = .01; Fig. 1) without adverse effects. The psyllium group consumed 12 g 
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per day to match the highest SM dose. Treatment compliance was addressed during the 
last 7 days of each month during the 3-month treatment period. Compliance was set at 75% 
a priori; this was determined by assessing the number of days all capsules were taken by 
the 21 days recorded. 
 
 
 
Figure 1. Fecal butyrate concentrations (n = 3) before and after 4 weeks of 9-g starch-
entrapped microsphere supplementation in a 1-group, open-label pilot study. Butyrate 
concentrations analyzed by Mann-Whitney U test and expressed as μmol/g of dry fecal 
weight. Values are means ± SD. 
 
2.3. Assessment of gastrointestinal clinical outcomes 
Structured questionnaires were used to assess impact of fiber supplementation on bowel 
habit and gastrointestinal symptoms. A Gastrointestinal Symptom and Severity Checklist 
containing 34 items was completed at all study visits to assess the presence of gastrointes-
tinal symptoms. This tool asked participants to rank the severity of their symptoms based 
on an 11-point scale (score of 0–10 with 10 being most severe). In addition, a 10-item tool 
to assess adverse effects of treatment was completed during the last week of each of the 
3 months during the treatment period; these questions were a subset of the questions on 
the Gastrointestinal Symptom and Severity Checklist and included bloating, abdominal 
pain, indigestion, passing gas, belching, heartburn, acid reflux, regurgitation of food, early 
fullness, and after-food fullness. At these same time points, stool frequency was assessed 
by having participants indicate the number of bowel movements daily, and stool con-
sistency was quantified by the Bristol Stool Scale [16]. Abnormal stool consistency was 
operationalized as types 1 and 2 (“constipated” stool) and 5–7 (“diarrheal” stool). The change 
in self-reported bowel habit was additionally assessed between the beginning and end of 
the treatment period by 6 questions asking about change in severity of constipation, stool 
frequency, completeness of bowel movements, stool consistency, ease of defecation, and 
overall well-being. Perceived improvement in physical and mental health was assessed 
through the SF-12v2 instrument (Medical Outcomes Trust, Boston, MA, USA). The SF-12v2 
consists of 12 questions with 3 to 5 response levels and is intended to assess both physical 
and mental functioning, represented by a Physical Component Summary score and a Men-
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tal Component Summary score, respectively. In addition, perceived improvements in con-
stipation severity were assessed through 6 questions that addressed change in severity of 
constipation, stool frequency, completeness of bowel movements, stool consistency, ease 
of defecation, and overall well-being. 
 
2.4. Stool SCFA measurement 
Stool samples were analyzed for SCFAs as previously described [13]. In brief, stool was 
centrifuged (12 000 rpm, 5 minutes), and a mixture of formic acid (20%), methanol, and 
2-ethyl butyric acid (internal standard, 2 mg/mL in methanol) was added to the superna-
tant. A 0.5-mL sample was injected onto a gas chromatography column (Stabilwax-DA, 
length 15 m, inner diameter 0.53 mm, film thickness 0.1 mm; Varian Chrompack, Bergen 
op Zoom, the Netherlands) in a Chrompack CP9001 gas chromatograph using an auto-
matic sampler (Chrompack liquid sampler CP9050; Varian Chrompack). Quantification 
was accomplished by measuring the peak areas for acetate, propionate, butyrate, and the 
branched-chain fatty acids isobutyrate and isovalerate relative to 2-ethyl butyric acid. 
SCFAs from visits 1 and 2 (2 weeks apart) at baseline were averaged to address variability 
in the samples. 
 
2.5. Stool microbiota collection and interrogation 
Participants collected stool using an anaerobic collection system (BD Gas Pak EZ Anaerobe 
Pouch System, Franklin Lakes, New Jersey, USA) and stored the sample in the refrigerator 
for a maximum of 24 hours before the scheduled visit. Once received, the stool samples 
were immediately stored at −80°C until used for microbiota interrogation. The microbial 
community was assessed for stool samples obtained at visit 2 (before treatment) and visit 
3 (after completion of treatment). Genomic DNA was extracted from fecal samples using 
the FastDNA Spin Kit for Soil (MP Biomedicals, Solon, Ohio 44139, USA) according to the 
manufacturer’s recommended protocol. The extracted DNA was quantified using the 
Qubit dsDNA BR Assay and the Qubit 2.0 Fluorometer (Life Technologies, Grand Island, 
New York, USA). Genomic DNA was polymerase chain reaction amplified using the pri-
mers 5′-GAGTTTGATCNTGGCTCAG-3′ and 5′-GTNTTACNGCGGCKGCTG-3′ targeting 
the V1–V3 region of bacterial 16S rRNA genes, and prepared for sequencing on a Roche 
454 GS FLX pyrosequencing instrument at the Research and Testing Laboratory (Lubbock, 
Texas, USA), as described previously [17]. Raw SFF files were imported into the software 
package CLC genomics workbench (v8; CLC bio, Qiagen, Aarhus, Denmark). Data were 
quality trimmed (Q < 0.03), and sequences shorter than 250 bases after trimming were re-
moved from the data set. Each sample was exported as a FASTA file and rarefied to 2000 
sequences per sample [18]. Samples were then processed using the QIIME software pack-
age (v1.8.0) [19]. Briefly, sequences were screened for chimeras using the USEARCH61 
algorithm [20], and putative chimeric sequences were removed from the data set. Data 
were pooled and clustered into operational taxonomic units (OTU) at 97% similarity using 
the USEARCH61 de novo OTU picking algorithm. Subsequently, representative sequences 
from each OTU were extracted, and these sequences were classified using the assign tax-
onomy uclust algorithm utilizing the Greengenes reference database (v13_8) [21]. A bio-
logical observation matrix containing all the grouped taxonomy of each individual OUT 
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was generated [22]. Alpha-diversity (within-sample) and beta-diversity (between-sample) 
metrics were calculated within the software package Primer6 (Primer-E Ltd, Plymouth, 
UK). Data from the entire data set were visualized using nonmetric multidimensional scal-
ing using Bray-Curtis similarity. Analysis of similarity was performed on the similarity 
matrix to determine if there were significant effects of treatment (starch type group) or visit 
(before or after treatment) on patient fecal microbial community. Diversity indices were 
calculated based on the untransformed data, equalized to the same number of sequences 
[18]. Taxon-by-taxon analyses were performed to determine if the relative abundance of 
individual taxa was significantly different between treatments and sampling time points 
using the group significance algorithm implemented within QIIME. Taxa below a 1% 
threshold were removed from the group significance test (Kruskal-Wallis test), and a false-
discovery rate (FDR) correction was applied. The amplicon sequence data from this study 
have been submitted to the NCBI Sequence Read Archive (SRA; https://urldefense 
.proofpoint.com/v2/url?u=http-3A__www.ncbi.nlm.nih.gov_Traces_sra_sra.cgi&d=CwIB 
aQ&c=XxU8ngzB_WPJXKyiin_6iQ&r=ZkwUjLY6PMt39iYSfGuwuIjGIktHOmd7xBfM-
iVmlpI&m=qsCZee47BbhooXFNIaJRZGrQQnwiLT8BeCVrhHiZV1g&s=GbBM30WUl3C 
BiuknSS83Dh1alncWJKn7dvv7MywznLQ&e=) under the BioProject (PRJNA385004) ac-
cession number SUB2628611. 
 
2.6. Statistical analyses 
Descriptive statistics were performed for normally distributed continuous measures using 
means and standard deviations and non-normally distributed variables using medians 
and interquartile range. Categorical measures were reported using frequency distributions 
and medians and interquartile range. Descriptive measures were compared using 1-way 
analysis of variance for continuous measures normally distributed, Kruskal-Wallis test for 
measures not normally distributed, and χ2 test statistic for percentages. For all outcomes, 
an intent-to-treat analysis was completed with the 43 participants that completed the treat-
ment period. Change in gastrointestinal symptoms and quality of life (SF-12 scale) were 
assessed between and within the groups (9 or 12 g SM and 12 g psyllium) at the 3 visits 
using a generalized estimating equations (GEE) approach with identity link function and 
an exchangeable correlation matrix. A P value of < .05 was set as the level of significance 
for all results. Data were analyzed with SAS software (version 9.1; SAS Institute, Cary, 
North Carolina, USA); dietary intake data were entered using Food Processor version 10.9 
(esha Research; Salem, Oregon, USA). 
The power for this study was based on a χ2 test statistic to compare the proportion of 
participants with adverse effects between the psyllium control arm and the 2 treatment 
groups. Based on prior experience, the proportion of participants in the psyllium group 
with adverse effects was expected to be approximately 80%, and we hypothesized that the 
SM supplement would reduce the adverse effects by half, nearly 40%. Thus, we would 
have 90% power to detect this difference in proportions between the control and treatment 
arms with an error rate of 5%. If the differences in proportions were smaller, say, SM re-
duced adverse effects by 60% of that in psyllium, then the power drops to 75%. 
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3. Results 
 
3.1. Participant characteristics 
Of the 68 participants enrolled, 63 returned for visit 2 after the 2-week run-in, and 43 re-
turned for the posttreatment visit at the end of the 3 months (visit 3) (Fig. 2). Of the 43 that 
completed the treatment period, 13 were in the 12-g psyllium group, 15 in the 9-g SM 
group, and 15 in the 12-g SM group (38.1%, 25.0%, and 31.8% attrition in each group, re-
spectively); although the highest attrition occurred in the psyllium group, no significant 
differences in attrition existed between groups. The demographic characteristics of partic-
ipants at baseline are listed by treatment group (n = 43) in Table 1. The mean (± SD) age of 
all participants was 42.6 ± 11.9 years, 69.8% were female, 55.8% were African American, 
and average BMI was 30.1 ± 7.6 kg/m2. A total of 80.0% of the participants had greater than 
12 years of education, and 55.6% were employed. No differences in baseline characteristics 
existed between groups or between those that were randomized to treatment (n = 63) and 
those that completed the study (n = 43). All analyses were performed with those complet-
ing the treatment period (returned for visit 3; n = 43). 
 
 
 
Figure 2. Participant screening, enrollment, and attrition. SM indicates starch-entrapped 
microspheres. 
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Table 1. Baseline characteristics of study participantsa 
 
Psylliumb 
(n = 13) 
SM 9 g 
(n = 15) 
SM 12 g 
(n = 15) 
Age, y 48.2 ± 10.3 41.9 ± 13.6 38.3 ± 10.2 
Female (%) 76.9 66.7 66.7 
Race (%)c 
     Black/African American 
61.5 40.0 66.7 
BMI (kg/m2) 30.5 ± 7.2 29.3 ± 8.7 30.5 ± 7.2 
Educationd (%) 
     > 12 y 
91.7 69.2 80.0 
Employment status (%) 
     Employede 
58.3 46.2 63.6 
Dietary fiber, g/1000 kcal 12.7 ± 3.6 12.1 ± 4.6 13.2 ± 6.1 
Abbreviations: SM, starch-entrapped microspheres; kcal, kilocalories. 
a. Baseline characteristics based on data obtained from those completing the trial (n = 43); data presented as 
means ± SD unless otherwise noted; no significant differences existed between groups at baseline by 
1-way analysis of variance or χ2 test. 
b. Psyllium dose = 12 g. 
c. Races other than African American include white (n = 12), Hispanic (n = 14), and Asian (n = 2). 
d. Psyllium, n = 12; 9 g SM, n = 13; 12 g SM, n = 10. 
e. Employed = full-time or part-time employment; those not employed included those that responded as 
unemployed, student, homemaker, or retired. Psyllium, n = 12; SM 9 g, n = 13; SM 12 g, n = 11. 
 
3.2. Dietary intake and supplement compliance 
Dietary intake (n = 42) was assessed through 7-day food records before and after the treat-
ment period to ensure that any changes seen in bowel habit and gut milieu were due to the 
fiber supplementation and not changes in dietary intake. No significant differences in die-
tary intake existed, including dietary components that may modulate bowel habit when 
examined by both total intake and intake/1000 k cal (239 kj). Specifically, total dietary fiber 
(Table 1), soluble fiber, and insoluble fiber did not differ between treatment groups within 
time point or change within groups over time (data not shown). Total fiber intake at base-
line for the entire group was below recommendations at an intake of 12.6 g/1000 kcal of 
fiber per day, with soluble fiber intake at 1.0 g/1000 kcal. The average energy intake was 
1389 kcal (332 kj) a day, indicating that the participants likely underreported when docu-
menting their dietary intake. None of the participants reported taking dietary supplements 
that would impact bowel habit such as prebiotics, probiotics, or supplemental dietary fiber. 
Of those that reported complete compliance data (n = 39), 85% were considered compliant. 
No differences in compliance existed between groups. All participants that completed the 
study were included in the analyses independent of compliance. 
 
3.3. Tolerability and gastrointestinal symptoms 
At baseline and each month of the 3-month treatment period, gastrointestinal symptoms 
were assessed to determine changes in these symptoms between groups over time and to 
determine tolerability of the fiber supplements. Of the 10 symptoms assessed, 6 were dif-
ferent between groups (bloating, abdominal pain, indigestion, passing gas, belching, heart-
burn; P < .05) at baseline. Change in the summed score for each of these parameters 
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between groups was not statistically significant. However, change between groups with 
treatment for several parameters including abdominal pain and bloating showed trends 
toward differences between groups (Fig. 3). 
 
 
Figure 3. Change in abdominal pain and bloating during supplementation at months 1–3 
with either psyllium, 9 g SM, or 12 g SM. Change in symptoms scores were compared 
with baseline symptoms before treatment (visit 1). Symptom change reported as summed 
scores from a 7-day symptom diary and analyzed by GEE. SM indicates starch-entrapped 
microspheres. Values are means ± SD. 
 
3.4. Bowel habit 
At baseline (visit 1), both 9- and 12-g SM treatment groups had a lower percentage of those 
with normal consistency (type 3 or 4) than psyllium, with 33.8% and 24.2% with normal 
stool consistency at baseline, respectively, vs. 62.2% in the psyllium group (P < .012) (Table 
2). At the end of the 3-month supplementation period, the percentages of participants who 
reported normal stool consistency were similar in all 3 groups; the percentages with nor-
mal stool consistency were 56.7%, 48.0%, and 45.7% for psyllium, SM 9 g, and SM 12 g, 
respectively. 
 
Table 2. Percentage of participants with normal stool consistency 
at baseline and treatment enda,b 
Treatment Baseline Month 3 
Psyllium 62.2 ± 7.0 56.7 ± 8.7 
SM, 9 g 33.8 ± 7.5* 48.0 ± 10.3 
SM, 12 g 24.2 ± 8.8* 45.7 ± 9.8 
Abbreviations: SM, starch-entrapped microspheres. 
a. Values are means ± SDs. 
b. Psyllium dose = 12 g. 
* P < .05 for differences from psyllium at baseline; GEE analysis. 
 
Mean bowel movement frequency increased with psyllium intake (P = .0003) from base-
line to treatment end (9.8 ± 0.1 bowel movements per week vs. 14.0 ± 0.2 bowel movements 
per week). The number of bowel movements per week in the 9- and 12-g SM groups also 
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increased from 9.8 ± 0.1 to 11.9 ± 0.2 and from 9.8 ± 0.2 to 12.6 ± 0.2 bowel movements, 
respectively; this increase was not significantly different than the increase in the psyllium 
group over time. 
When self-reporting improvement in bowel habit, participants in all 3 groups experi-
enced a “minimally better” (4 of 5) or “significantly better” (5 of 5) change in all 6 param-
eters of bowel habit after supplementation, with no significant differences between groups 
for each of the 6 parameters (Table 3). 
 
Table 3. Self-reported improvement in bowel habit after supplementation in participants consuming 
psyllium or SMa 
 Psylliumb 
(n = 10) 
SM 9 g 
(n = 12) 
SM 12 g 
(n = 14) 
Constipation severity 5.0 (0.5) 5.0 (2.0) 5.0 (1.8) 
Stool frequency 5.0 (0.5) 4.5 (2.0) 5.0 (1.0) 
Bowel movement completeness 5.0 (0.5) 4.0 (2.0) 5.0 (1.8) 
Stool consistency 5.0 (0.0) 4.5 (2.0) 5.0 (1.8) 
Ease of defecation 5.0 (0.3) 5.0 (2.0) 5.0 (1.0) 
Overall well-being 5.0 (0.3) 4.0 (2.0) 4.5 (2.0) 
Abbreviations: SM, starch-entrapped microspheres. 
a. Based on a scale of 1–5 with 1 = significantly worse, 2 = minimally worse, 3 = no change, 4 = minimally 
better, and 5 = significantly better. Data presented as median (IQR) as a calculated range; no significant 
difference in improvement between groups by GEE analysis. 
b. Psyllium dose = 12 g. 
 
3.5. Quality of life 
Baseline SF-12 scores assessed functional health 5 five parameters for both physical and 
mental health. Physical and mental components scores before and after treatment were 
49.9 and 47.7, 49.2 and 51.2, and 51.8 and 44.1 for the psyllium, 9-g SM, and 12-g SM groups, 
respectively; the differences between these scores were not significant. In addition, the SF-12 
scores approximated the SF-12 mean scores of the general US population (score of 50) for 
all parameters and all treatment groups. 
 
3.6. Gut microbial community structure 
No significant effect on alpha diversity was observed between the different treatment groups; 
for example, the average group Shannon index ranged from 2.20 to 2.64 between the 6 
groups (3 treatment groups by 2 visits [2 and 3]) (Fig. 4). Likewise, 2-way analysis of simi-
larity (group and visit) did not indicate a significant difference in microbial community 
across the different groups or visits (global R statistic = −0.005, P = .559, 999 permutations). 
Analysis of similarity did indicate a significant effect of individual patient on gut microbial 
community (global R statistic = 0.474, P = .0001, 9999 permutations). We observed that, in 
many individuals, the gut microbial community was fairly stable across the 2 visits and 
within a clustering of overall Bray-Curtis similarity of 60 or higher (scale 0–100). In several 
individuals from each treatment, visit 2 and visit 3 gut microbial community structure was 
significantly divergent, but no systematic association with treatment was observed. No 
significant effect of compliance was observed. 
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Figure 4. Microbial taxonomic composition of fecal samples based on 16S rRNA gene am-
plicon sequencing from genomic DNA extracts. Raw sequence data (rarefied to 2000 se-
quences/sample) were clustered (97%) and annotated as described in the text. Annotation 
data were summarized at the taxonomic level of genus, and the number of sequences from 
each taxon for each sample are presented as a bar plot. Samples are grouped by treatment 
group (psyllium, 9 g SM, 12 g SM) and visit (2 or 3). For each group, the average Shannon 
index and standard deviation are shown. SM indicates starch-entrapped microspheres. 
 
A taxon-by-taxon analysis did not reveal any individual taxon (across all taxonomic 
levels) with significant differences, as determined using Kruskal-Wallis nonparametric 
test, adjusted using the Benjamini-Hochberg FDR correction. When examining taxa with-
out correcting for FDR, differences in Coriobacteriaceaeae were observed (P = .04); how-
ever, because of high variability, this change was not significant when corrected with FDR. 
The lack of taxa with significant differences appears to be the result of the incidence of 
many individuals with low relative variation between the 2 visits, whereas other individ-
uals had extreme variation; this was observed across all 3 treatment groups. Thus, the var-
iation across each sample size led to the lack of significant effects across the study. For 
example, there was high variation in the relative abundance of bacteria from the genus 
Prevotella, ranging from no detected sequences (49 samples of 82) up to 1732 sequences (of 
2000). We note that, although not significant, the general trends in all 3 patient groups were 
toward higher relative abundance of Bacteroidetes from visit 2 (before treatment) to visit 
3 (after treatment); part of this is due to the increase in average abundance of sequences 
from Prevotella (phylum Bacteroidetes) from visit 2 to 3 in all treatments. A majority of the 
Prevotella was P. copri, with few samples containing P. stercorea. 
 
3.7. Short-chain fatty acids 
SCFA analysis was performed in stool collected at baseline (visit 1 and 2) and treatment 
end (visit 3) for those that completed the treatment period. There were no differences in 
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mean total SCFA or individual SCFA (propionate, acetate, and butyrate) between the 3 
groups at baseline or from baseline to treatment end (Table 4). Similarly, branched-chain 
fatty acids (BCFAs) and the ratio of SCFAs/BCFAs did not significantly change with treat-
ment despite an increase in the ratio in the 9-g SM group. Trends in overall SCFA and 
butyrate decreases from baseline were seen in the psyllium group compared with no 
change in both in the SM groups. In addition, although only 28.6% of participants in the 
psyllium group experienced increases in SCFA from baseline to treatment end, 53.3% of 
participants in the 9-g SM group and 43.8% of participants in the 12-g SM group experi-
enced increases in SCFA with treatment. 
 
Table 4. Short-chain fatty acids before and after treatment in participants consuming psyllium or SMa 
 Psylliumb 
(n = 13) 
SM 9 g 
(n = 13) 
SM 12 g 
(n = 13) 
Total SCFA, μmol/gc    
     Baseline 100.1 (128.3) 52.1 (29.2) 76.7 (40.6) 
     Visit 3 67.4 (44.3) 54.4 (35.2) 76.9 (45.7) 
Butyrate, μmol/g    
     Baseline 25.6 (21.2) 10.6 (7.5) 14.4 (13.0) 
     Visit 3 13.4 (9.2) 11.2 (8.5) 11.8 (14.6) 
Butyrate, mol%    
     Baseline 20.2 (7.5) 18.2 (10.4) 20.6 (4.7) 
     Visit 3 17.0 (7.8) 18.4 (5.1) 19.4 (12.0) 
Acetate, μmol/g    
     Baseline 62.3 (33.1) 32.5 (24.6) 42.0 (18.7) 
     Visit 3 42.7 (26.5) 34.4 (25.0) 32.3 (13.4) 
Propionate, μmol/g    
     Baseline 19.0 (26.0) 11.1 (5.9) 16.7 (12.5) 
     Visit 3 14.7 (12.6) 11.6 (7.6) 13.4 (15.0) 
Isobutyrate, μmol/g    
     Baseline 1.1 (2.1) 1.6 (1.0) 1.8 (0.7) 
     Visit 3 1.6 (1.0) 1.0 (1.0) 1.7 (1.9) 
Isovalerate, μmol/g    
     Baseline 1.8 (2.3) 2.4 (1.6) 2.8 (1.0) 
     Visit 3 2.1 (0.9) 1.7 (1.0) 3.0 (3.1) 
BCFA, μmol/g    
     Baseline 2.8 (4.5) 3.8 (2.6) 4.6 (1.6) 
     Visit 3 3.8 (1.9) 2.7 (2.2) 4.8 (4.8) 
SCFA/BCFA    
     Baseline 32.5 (32.1) 18.6 (18.1) 16.3 (9.1) 
     Visit 3 18.4 (28.3) 24.0 (24.2) 11.0 (5.4) 
Butyrate/SCFA    
     Baseline 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 
     Visit 3 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 
Abbreviations: SCFA, short-chain fatty acid; BCFA, branched-chain fatty acid. 
a. Data are presented as median (IQR) as a calculated range; no significant difference in SCFA or BCFA 
between groups at baseline or treatment end by Kruskal-Wallis test. 
b. Psyllium dose = 12 g. 
c. Data are presented as μmol/g of dry fecal weight. 
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4. Discussion 
 
The potential impact of a fiber on health is well appreciated. Use of fiber was initially pop-
ularized for management of constipation; however, in addition to conventional bulking 
fibers that are marketed for treatment of constipation, fermentable fibers have recently also 
become available. These fermentable fibers are termed prebiotics and can be defined as “a 
selectively fermented ingredient that allows specific changes, both in the composition 
and/or activity in the gastrointestinal microflora that confers benefits upon host well-being 
and health” [23]. Researchers have demonstrated the key role of intestinal microbiota in 
several metabolic and inflammatory disorders and have highlighted the importance of 
availability of fermentable carbohydrates in the colon for maintaining healthy microbiota 
composition and function [24,25]. Thus, it is not surprising that fiber supplementation is a 
common recommendation by many health professionals and scientists alike; this is also 
evident, as recent expenditures on fiber supplements in the United States were approxi-
mately $300 million [26]. 
Coinciding with the recent surge of fermentable fiber research and availability, tolera-
bility of fermentable fiber intake has become an area of concern. In fact, in some cases, 
individuals with gastrointestinal conditions (e.g., irritable bowel syndrome) are recom-
mended to reduce their intake of foods containing certain prebiotics (e.g., low-FODMAP 
[fermentable, oligo-, di-, mono-saccarides and polyols] diet) [9]. This is, at least in part, due 
to the fast-fermenting nature of most prebiotics such as inulin and fructo-oligosaccharides, 
which are fermented by bacteria in the right-sided colon and cecum and do not reach the 
distal colon where the majority of bacteria are present. This fast-fermenting nature results 
in no benefit to or exacerbation of symptoms such as gas production and bloating [10,11]. 
Thus, it is plausible that onset and rate of fermentation of fermentable fiber products dic-
tate the frequency and severity of associated adverse effects, and those fibers with delayed, 
slow fermentation rate should have fewer adverse effects. Indeed, our in vitro and ex vivo 
stool fermentation studies in test tubes and in an artificial colonic simulator showed that 
the SM fiber product has a slow and delayed fermentation profile [12,13]. Thus, slow and 
delayed fermentable fibers have a potential to be nonbloating fibers, and if they can also 
positively impact BM, they would be particularly desirable. Therefore, this study aimed to 
determine if SM are well tolerated, improve bowel habit, and impact the colonic milieu 
through modulation of microbiota and SCFA compared with psyllium, a commonly used 
fiber. 
Our hypothesis was only partially supported by the results of this study. We found that 
our study participants, who were primarily middle-aged women, reported improved 
bowel habit and stool frequency with intake of both types of fibers; these participants also 
had improved stool consistency with SM fiber at both doses. Although no statistically sig-
nificant differences were seen in tolerability and gastrointestinal symptoms between psyl-
lium and SM fibers, substantial differences in the change in specific bowel habits over time 
in the 9- and 12-g SM groups existed compared with psyllium. This could in part be due 
to the differences in baseline values of these bowel habits; both the 9- and 12-g SM groups 
had higher symptoms at baseline, thus causing more room for change over time. Although 
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not statistically significant, it should also be noted that attrition rate was higher and gas-
trointestinal symptoms less improved in the psyllium group. Our in vitro work compared 
gas production and fermentation profiles of various fibers, including psyllium and SM 
[12]. As psyllium-generated a high amount of gas in the first 4 hours after incubation with 
microbiota, we expected to see less tolerability and more gastrointestinal symptoms in the 
psyllium group. However, our clinical study did not fully support our prediction because 
although there was a trend for potential benefit of SM fiber, the differences between SM 
fiber and psyllium were not marked. 
Previous research supports improved stool consistency and increased stool frequency 
with psyllium intake in individuals with constipation [27,28]. In the current study, psyl-
lium did not significantly improve stool consistency. Although it is possible that SM is 
more effective at normalizing stool consistency compared with psyllium as seen in the cur-
rent study, a larger sample will be needed to determine if SM is truly more effective than 
psyllium at improving stool consistency or if baseline differences in stool consistency con-
tributed to the differing responses to the different fibers. A significant increase in stool 
frequency was seen equally in all 3 fiber groups in the current study. Although our partic-
ipants were not constipated by definition, the primary inclusion criterion was “unsatisfac-
tory bowel habit.” This criterion allowed for inclusion of those with an average bowel 
movements of approximately 9–14 times per week, as stool consistency, incomplete defe-
cation, and ease of defecation satisfied the criteria of “unsatisfactory bowel habit.” Indeed, 
all 3 groups reported improved bowel habit at the end of 3 months. This improvement was 
expected in the psyllium group because more than half of constipated participants had 
improvements in global constipation symptom scores in previous research [27]. We now 
show that SM fiber has a similar positive impact on “unsatisfactory bowel habit” when 
compared with psyllium fiber. Despite this improvement, no difference in SF-12 scores 
was seen with treatment; this could have been because of relatively high subcomponent 
scores at baseline. Currently, limited data exist for the benefit of psyllium on quality of life 
in constipated individuals; a recent review in those with irritable bowel syndrome con-
cluded that psyllium did not increase quality of life [29]. 
Based on our prior in vitro work that indicates that SM positively alter microbiota com-
position in the stool and increase production of butyrate through the entire colon [12–14], 
we hypothesized that SM fiber intake would lead to significant change in microbiota com-
position and increased SCFA production. However, this was not supported because we 
found that microbiota composition and SCFA were largely unchanged with SM fiber treat-
ment. In addition, the impact of fiber supplement on microbiota in the current study was 
minimal in not just SM but all 3 fiber groups, with the primary impact on changes in 
Prevotella in select participants. The biological importance of changes in abundance of 
Prevotella is not clear. For example, select participants responded to a 3-day consumption 
of kernel-based bread as indicated by a higher Prevotella to Bacteroides ratio than nonre-
sponders [30], but several pathological states like HIV infection are also associated with 
higher Prevotella abundance [31]. As individual species within the Prevotella genus were 
not identified, it is possible that changes in Prevotella after SM intake could be originating 
from increases in beneficial strains. 
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Although total SCFA was not significantly different with supplementation in any group 
in the current study, the percentage of individuals with increased SCFA with treatment 
was greater in both SM groups compared with psyllium. In addition, micromoles per gram 
of butyrate, acetate, and propionate all tended to decrease with psyllium intake while re-
maining unchanged in the SM groups; however, we acknowledge that these changes were 
not significant. Salyers et al. [32] suggest that psyllium may be fermentable because of the 
presence of arabinoxylans, but the complex nature of these highly branched arabinoxylans 
[33] may cause incomplete fermentation of psyllium with little or no effect on SCFA pro-
duction. The lack of fermentibility or incomplete and limited fermentibility of psyllium is 
supported by our findings as well as prior studies in humans in which intestinal gas is not 
increased with psyllium intake, indicating a lack of fermentable properties [6,34,35]. It 
should, however, be noted that our findings cannot definitely exclude fermentation capac-
ity of psyllium or SM fiber because (1) SCFA measurements are highly variable, and stool 
SCFA may not reflect true SCFA production in the intestine [36], and (2) dietary intake can 
have strong short-term influences on microbiota [37], and not recording dietary intake the 
day before stool collection limited the ability to adjust for the influence of dietary intake 
on microbiota and SCFA. A larger sample size and assessment of microbiota composition 
and SCFA measurement at multiple time points are needed to determine if SM impacts 
microbiota composition and SCFA production in a way that differs from psyllium. 
Strengths of this study include use of validated or structured questionnaires to assess 
outcomes; randomized, double-blind, controlled study design; and provision of dietary 
fibers at high doses to be able to determine if these fibers have beneficial impacts on bowel 
habit and gut health. Assessing dietary components that may impact bowel habit allowed 
us to attribute the changes in bowl habits to the fiber supplement and not changes in die-
tary intake. As the low-fiber background diet in this study is similar to the general popu-
lation [38], the impact of the fiber supplements in this study may be generalizable to the 
population with unsatisfactory bowel habits. 
Our primary limitation was that our study was underpowered to see differences in our 
outcomes between treatment groups. In the current study, enrollment proved to be diffi-
cult, and attrition was relatively high, with 68% of those starting the study retained until 
treatment end. As there were no significant differences in dropout rates between groups, 
it is unlikely that the participants dropped out because of difficulties with treatment. We 
believe that attrition was due in part to the treatment length of 12 weeks. In addition, lack 
of randomization effectiveness is a limitation. We attempted to use propensity scoring to 
correct for imbalances in baseline data, but as we did not see any differences in baseline 
values of other variables, we were unable to perform propensity scoring. Also, stool sam-
ples were stored without acidification, potentially reducing SCFA concentrations in the 
samples. Lastly, significant interindividual variability in microbiota composition and stool 
SCFA levels compromised our ability to detect statistically significant impact of the fibers. 
Our study suggests that a crossover design might be more suitable than a parallel design 
for assessing impact of fibers with potential prebiotic capacity to overcome this interindi-
vidual variability in microbiota composition and response to supplements. 
In summary, recent advances in carbohydrate science are providing alternatives to con-
ventional fibers such as psyllium, but commonly used fast-fermenting prebiotics like 
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fructo-oligosaccharides and inulin may cause gastrointestinal adverse effects and not pro-
vide benefit to the entire colon when consumed. Development of a novel, slowly ferment-
ing fiber has the potential to address the need for a fiber that produces SCFAs and 
beneficially modulates gut microbiota and gut health while not creating adverse effects 
when consumed. Taken together, the current data support improved bowel habit with fi-
ber intake for those with self-reported constipation. It appears that consumption of SM 
may have an advantage over psyllium for improvement in stool consistency, but definitive 
differences in this outcome as well as in microbiota and SCFA between fiber types for those 
with self-reported constipation will need to be determined in a larger sample. 
 
Acknowledgments – The authors would like to thank Nazia Kazmi (clinical coordinator) for recruit-
ing study participants and assisting the investigators during the conduct of the study. This work was 
supported by the National Institutes of Health, National Institute of Diabetes and Digestive and Kid-
ney Diseases, and Small Business Innovation Research grant (DK088525-01). Ali Keshavarzian and 
Bruce Hamaker are holders of the patent for the starch-entrapped microspheres (patent is pending) 
and are part owners of Nutrabiotix LLC, the company that has the sole right of license of the product. 
Ali Keshavarzian and Bruce Hamaker were involved in study design and preparation and submis-
sion of the application for the Small Business Innovation Research grant but did not participate in 
participant assessment or data analysis. Both Ali Keshavarzian and Bruce Hamaker participated in 
preparation of the manuscript after the data were analyzed and finalized. 
 
Glossary 
 
Unsatisfactory bowel habit   Defined by any of the following conditions: < 3 bowel movements per 
week, hard stool requiring straining, or sense of incomplete defecation. 
Prebiotic   A selectively fermented ingredient that allows specific changes both in the composition 
and activity in the gastrointestinal microflora that confer benefits upon host well-being and 
health. 
Short-chain fatty acid   Fatty acids of less than 6 carbons created as metabolite of gastrointestinal 
microbial fermentation. 
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